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Angiogenesis is essential for tumours to grow beyond 2–3 mm3 in
size (Folkman, 1975, 1989). It has been demonstrated that specific
angiogenesis inhibitors can inhibit tumour growth in animal
models (Folkman, 1997). A continuing goal of our laboratory is to
develop therapies for cancer patients that specifically block the
angiogenic process.
Although angiogenesis is important for tumour growth and fetal
development, it is also involved in inflammation and wound
healing (Folkman, 1995). Anti-inflammatory agents are known to
interfere with wound healing and pathological angiogenic disor-
ders like rheumatoid arthritis and osteoarthritis (Insel, 1996). Anti-
inflammatory agents, such as dexamethasone and NSAIDs, inhibit
inflammatory-induced angiogenesis, caused by cauterization or by
laser (Haynes et al, 1989; Sakamoto et al, 1995). Except for
steroidal agents and indomethacin, anti-inflammatory agents have
not been shown to inhibit non-inflammatory angiogenesis
(Folkman and Ingber, 1987; Silverman et al, 1988).
In animal tumour models, NSAIDs, such as indomethacin, have
been reported to inhibit tumour growth and to potentiate the effect
of chemotherapy or radiotherapy (Fulton, 1984; Lynch et al, 1978;
Teicher et al, 1994). Clinically, it has been observed that intake of
NSAIDs correlates with a reduced degree of neovascularization in
the granulation tissue of patients with gastroduodenal ulcers
(Hudson et al, 1995). Sulindac also caused regression in the
number and size of adenomas in patients with familial adenoma-
tous polyposis (Labayle et al, 1991; Giardiello et al, 1993).
In this study, we tested clinically available, oral anti-inflamma-
tory drugs for their antiangiogenic activity in the corneal neo-
vascularization assay, a growth factor-induced non-inflammatory
angiogenesis model (Kenyon et al, 1996). We have previously
demonstrated that thalidomide can inhibit growth factor-induced
angiogenesis in rabbits and mice (D’Amato et al, 1994; Kenyon et
al, 1997). Therefore, we investigated whether NSAIDs were able
to enhance the antiangiogenic effect of thalidomide. Based on the
results of the corneal neovascularization assay and as sulindac is a
safe drug for long-term treatment (Insel, 1996), we also deter-
mined the anti-tumour effect of the oral combination of thalido-
mide and sulindac in a rabbit tumour model.
MATERIALS AND METHODS
Drugs
The NSAIDs aspirin, phenidone, quercetin, esculetin, nordi-
hydroguiaretic acid (NDGA), acetominophen, ibuprofen, sulindac
and indomethacin were purchased from. Sigma Chemical Co. (St
Louis, MO, USA). The following compounds – sulindac sulphone
and sulindac sulphide (metabolites of sulindac), a specific
cyclooxygenase 2 inhibitor (NS398), methylheptyl imidazole and
furegrelate sodium (thromboxane inhibitors) and SKF525AHCL,
an inhibitor of thromboxane while inducing prostaglandin produc-
tion by endothelial cells – were all obtained from Biomol Research
Laboratories (Plymouth Meeting, PA, USA). In mice, drugs were
given at the highest tolerated dose, determined as the maximum
dose not associated with signs of toxicity, as measured by weight
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loss, hair loss, infection and lethargy during 5 or 6 days of treat-
ment. We screened these drugs for antiangiogenic activity by
either s.c. or i.p. injections because we wanted to avoid any varia-
tion in the assay due to differences in absorption. After this initial
screen, we confirmed the inhibitory effect of the most potent
agents when orally administered.
Mice and rabbits
Six- to eight-week-old C57B16 male mice were obtained from
Jackson Laboratories (Bar Harbor, MA, USA). New Zealand
White female rabbits (1.5 kg) were ordered from Charles River
(Wilmington, MA, USA). Both species were housed in the animal
research facilities of Children’s Hospital.
Corneal micropocket assay
In the stroma of the mouse cornea adjacent to the limbus, pellets
were implanted with bFGF or VEGF as described previously
(Haynes et al, 1989). In brief, after anaesthetizing the mice,
0.4 ´ 0.4 mm2 pockets were made in the cornea. Subsequently,
80-ng bFGF or 160-ng VEGF pellets were implanted 1.0–1.2 mm
or 0.5–0.7 mm from the limbal vessels respectively. Then,
erythromycin was topically applied (E Fougera, Melville, NY,
USA). The vascular response to the bFGF or VEGF pellets was
measured 5 or 6 days after implantation, respectively, by maximal
vessel length and number of clock hours of neovascularization.
The area of corneal neovascularization was calculated by using a
modified formula of a half ellipse, that best approximates the
area of neovascularization: area (mm2) = [ p´clock hours ´
length (mm) ´ 0.2 mm].
Tumour assay
Female New Zealand White rabbits were used for propagating the
V2 carcinoma. This tumour originates from a Shope virus-induced
papilloma (Kidd and Rous, 1940). Small 0.5 ´ 0.5 cm2 pieces were
implanted intramuscularly in the right thigh. Treatment was started
at day 10 after tumour implantation, when the mean volume of the
tumour was 6 cm3. Rabbits were sacrificed 17 days after the start
of treatment when the mean volume of control tumours was
120 cm3. Length and width of tumours were measured to calculate
tumour volume with the formula: length ´ (width)2 ´ 0.52 =
tumour volume. All experiments were conducted in accordance
with the Animal Care and Use Committee.
Immunohistochemistry
Tumour tissues were fixed in Carnoy’s fixative overnight and
embedded in paraffin according to standard histological proce-
dures. Carnoy’s fixed tissue sections (5–8 mm) were pretreated
with 2 mg ml–1 proteinase K (Boehringer Mannheim, Mannheim,
Germany) at 37°C for 15 min before staining with a goat poly-
clonal antibody against human von Willebrand factor (1:1500 dilu-
tion; Incstar, Stillwater, MN, USA). Positive staining was detected
by incubating sequentially with a biotinylated horse anti-goat
secondary antibody (Vector Laboratories, Burlingame, CA, USA),
avidin–horseradish peroxidase, chromagen and counterstained
with haematoxylin. Microvessel density was determined by light
microscopy according to the procedure of Weidner et al (1991).
Each count was expressed as the number of microvessels identi-
fied within a selected 250´ field. At least three separate 250´
fields were analysed for each tumour specimen.
Statistical analysis
The unpaired Student’s t-test was used to test whether inhibitory
activity was significantly different from controls. ANOVA (Instat
Mac package) was performed to test whether combination treat-
ment was significantly different from either agent alone.
Significant difference was determined as P-value < 0.05.
RESULTS
Mouse corneal micropocket assay
Inhibition of corneal neovascularization in mice by single anti-
inflammatory drugs ranged from 0% to 60% in both bFGF and
VEGF assays, summarized in Table 1. Sulindac (25 mg kg–1 day–1
s.c.) and indomethacin (5 mg kg–1 day–1 s.c.) were the most potent
inhibitors of angiogenesis induced by bFGF [50% (n = 15,
P < 0.01) and 59% (n = 21, P < 0.01) respectively] and by VEGF
Table 1 Inhibitory effect of non-steroidal anti-inflammatory drugs in the corneal neovascularization assay stimulated by bFGF or VEGF
NSAID Dose (mg kg–1) Per cent inhibition nP -value
bFGF VEGF
Acetaminophen 100a 0– 8 n s
Aspirin 10–160a 0–11 – 8 ns
NDGA 25b 30 – 8 ns
Esculetin 200c 15 – 8 0.02
Phenidone 100b 17 – 8 < 0.01
Quercetin 300c 18 – 8 < 0.01
Ibuprofen 25b 6 8 23/8 ns/ns
Ketoprofen 80b 30 41 8/8 < 0.01
Indomethacin 5b 59 61 15/21 < 0.01/< 0.01
Sulindac 25b 50 55 15/15 < 0.01/< 0.01
aoral; bs.c.; ci.p. Inhibitory effect is expressed in percentage representing the area of corneal neovascularization induced by either bFGF or VEGF compared with
controls (n = 8 per experiment) of the experiments in which that particular drug was tested; n = the number of eyes that were tested. Drugs were given once
daily s.c., i.p. or orally.116 HMW Verheul et al
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[55% (n = 15, P < 0.01) and 61% (n = 21, P < 0.01) respectively].
Orally administered sulindac (30 mg kg–1 twice daily) and
indomethacin (5 mg kg–1 day–1) caused a similar inhibition of
bFGF-induced neovascularization as the subcutaneous dosing
regime (n = 8, P < 0.01). Ketoprofen and ibuprofen were less
inhibitory for either bFGF- or VEGF-induced neovascularization.
In addition, the lipoxygenase inhibitors esculetin, quercetin,
phenidone and NDGA were less inhibitory in the bFGF-induced
neovascularization corneal pocket assay. Aspirin and aceta-
minophen had no inhibitory effect.
When sulindac (25 mg kg–1 day–1) was administered in combina-
tion with thalidomide (200 mg kg–1 day–1), the combined inhibitory
effect was significantly enhanced to 63% (n = 15, P < 0.01) for
bFGF and 74% (n = 16, P < 0.01) for VEGF (see Table 2).
Indomethacin, which has similar antiangiogenic effects as sulindac
as a single agent, did not enhance the inhibitory effect of thalido-
mide [67% (n = 15, P > 0.05) for bFGF and 61% (n = 21, P > 0.05)
for VEGF].
Sulindac is metabolized in vivo to the active metabolite sulindac
sulphide and the inactive metabolite sulindac sulphone (with
regard to the inhibitory activity of prostaglandin synthesis)
(Duggan et al, 1977). Sulindac sulphide inhibited bFGF-induced
neovascularization to a maximum of 34% (25 and 50 mg kg–1 day–1
s.c.,  n = 8 for each experiment, P < 0.01), whereas sulindac
sulphone inhibited 31% (25 mg kg–1 day–1 s.c., n = 16, P < 0.01).
The specific thromboxane inhibitors, carbomethylheptyl imida-
zole and furegrelate sodium, inhibited bFGF-induced neovascular-
ization by 32% (n = 6, P < 0.01) and 22% (n = 16, P < 0.01),
respectively, at the highest tolerated dose (40 mg kg–1 day–1 s.c.).
In addition, SKF525AHCL, an agent that inhibits thromboxane
production but induces prostaglandin production, showed 25%
inhibition (n = 8, P < 0.01). The specific cyclooxygenase 2
inhibitor NS-398 inhibited 25% at the highest tolerated dose of
20 mg kg–1 day–1 s.c. (n = 16, P < 0.01).
Rabbit V2 carcinoma model
V2 carcinoma, implanted in the thighs of control rabbits, grew in
27 days to about 70 g, which equalled 120 cm3 in volume, as
shown in Figure 1. Oral treatment with sulindac (60 mg kg–1 day–1)
or thalidomide (200 mg kg–1 day–1) inhibited tumour growth by,
respectively, 35% (n = 5, P < 0.01) and 55% (n = 14, P < 0.01), as
shown in Figure 1. When the two drugs were combined, inhibition
of tumour growth was enhanced to 75% (n = 10, P < 0.05, see
Figure 1). A lower dose of 25 mg kg–1 day–1 of orally administered
sulindac failed to inhibit tumour growth and did not enhance the
inhibitory effect of thalidomide (data not shown). Weight loss,
lethargy or hair loss was not observed during treatment.
Microvessel density is a parameter for tumour-induced angio-
genesis (Folkman, 1995). To determine whether this therapy
indeed affects tumour-induced neovascularization, we performed
immunohistochemical staining on these tumour tissues with a
polyclonal goat antibody against Von Willebrand factor that stains
the endothelium of rabbits (Tanaka et al, 1994). A significantly
reduced microvessel density (m.v.d.) was observed in the oral
combination therapy (control m.v.d. = 32 ± 4 vs sulindac/thalido-
mide therapy m.v.d. = 14 ± 4; n = 5, P < 0.01, per 200´ high-
power field).
DISCUSSION
The role prostaglandins play in neovascularization and tumour
growth is not clear, but anti-tumour activity of prostaglandin
synthetase inhibitors has been previously reported (Fulton, 1984;
Lynch et al, 1984; Teicher et al, 1994). The potential role of the
arachidonic acid cascade for tumour growth and metastases forma-
tion has been reviewed previously by Marnett (1992). Proposed
explanations for the inhibitory effects of prostaglandin synthetase
inhibitors on tumour growth included an antimutagenic effect,
a direct inhibitory effect on tumour cell proliferation and
prostaglandin production or an immunomodulating effect.
Alternatively, we hypothesized that prostaglandin synthetase
inhibitors may act by inhibiting angiogenesis and found that
sulindac and indomethacin were effective inhibitors of growth
factor-induced neovascularization.
Because sulindac and indomethacin are relatively selective for
prostaglandin H synthetase 1 (COX-1) compared with the others
we tested (Meade et al, 1993; Mitchell et al, 1993; Smith et al,
1994), our results suggests that COX-1 is important for non-
inflammatory neovascularization. However, although sulindac and
Table 2 Inhibitory effect of sulindac if combined with thalidomide in the
corneal neovascularization assay stimulated by bFGF or VEGF
Drug Dose (mg kg–1) Per cent inhibition n
bFGF VEGF
Thalidomide 200 41 40 31/39
Sulindac 25 50 55 15/15
Thalidomide + sulindac 200 + 25 63a 74a 15/16
aInhibitory effect is significantly different from either agent alone (P < 0.01,
tested by ANOVA). Inhibitory effect is expressed in percentage representing
the area of corneal neovascularization induced by either bFGF or VEGF
compared with controls (n = 8 per experiment) of the two experiments in which
the drugs were tested; n = the number of eyes that were tested with
bFGF/VEGF. Sulindac was given once daily s.c. and thalidomide once daily i.p.
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Figure 1 Effect of orally administered thalidomide and sulindac on tumour
growth of V2 carcinoma in rabbits. Ten days after implantation of a tumour
piece in the right thigh of New Zealand White female rabbits, treatment with
methylcellulose (n = 13), sulindac (n = 5), thalidomide (n = 14) or the
combination of thalidomide and sulindac (n = 10) was started for 17 days.
The combination of thalidomide and sulindac inhibited tumour growth by 75%
and was significantly different (P < 0.05) from either agent alone or the
control group. Oral treatment with sulindac or thalidomide inhibited tumour
growth by, respectively, 35% (n = 5, P < 0.01) and 55% (n = 14, P < 0.01).
The data were collected in three separate experiments and this figure
shows a representative experiment (thalidomide, 200 mg kg–1 p.o.; sulindac,
60 mg kg–1 day–1 p.o.; n = 5 per group. Each bar represents the standard
error of the meanThalidomide and sulindac inhibit angiogenesis and tumours 117
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indomethacin are relatively selective for COX-1, they are still
potent inhibitors of prostaglandin H synthetase 2 (COX-2).
NS398, a specific COX-2 inhibitor, also inhibited corneal neovas-
cularization, further indicating that both COX-1 and COX-2 are
involved. Aspirin, an irreversible cyclooxygenase inhibitor, lacked
an antiangiogenic effect. This absence of activity may be related to
the observation that the irreversible inhibition of cyclooxygenase
synthetases by aspirin resulted in a compensatory production of
COX-2 with bioactivity (Karim et al, 1995). Still, we cannot rule
out that some differences in antiangiogenic activity of the NSAIDs
were caused by a difference in pharmacokinetics.
Inhibitors of thromboxane (an enzyme that is exclusively found
in platelets) inhibited bFGF-induced corneal neovascularization.
This finding suggests that platelets may play a role in angio-
genesis, presumably because of their growth factor release upon
activation. Indeed, it has been reported that thrombopenia inhibits
tumour angiogenesis (Peterson, 1996).
The action of sulindac and its metabolites on corneal neovascu-
larization suggests that regression of tumours in patients with
familial adenomatous polyposis (FAP) (Labayle et al, 1991;
Giardello et al, 1993) may be in part mediated through blocked
angiogenesis. Indeed, significantly higher vessel counts have been
found in adenomas compared with normal mucosa of the colon,
whereas colon carcinomas showed higher vessel counts than
adenomas. This suggests that angiogenesis may be important for
polyp formation and for the transition to neoplasia (Bossi et al,
1995). We assumed that the inhibitory effect of sulindac was
mainly due to an inhibition of cyclooxygenases. However, the
inactive metabolite of sulindac, sulindac sulphone, which does not
inhibit cyclooxygenase and cannot be reformed to sulindac or
sulindac sulphide (Duggan et al, 1977) also inhibited corneal
neovascularization. It was in fact as potent as sulindac sulphide,
the active metabolite. Sulindac sulphone and sulphide have both
been shown to induce apoptosis in colon tumour cell lines inde-
pendent of cyclooxygenase synthetase inhibitory activity (Hanif et
al, 1996; Piazza et al, 1997). Furthermore, sulindac has recently
been demonstrated in a mouse model of FAP to regress tumours
independent of its effect on prostaglandin production (Chiu et al,
1997). Therefore, the antiangiogenic effects of sulindac in the
corneal neovascularization assay seem to be, at least partially,
mediated by other mechanisms not involving cyclooxygenases.
The search for non-toxic antiangiogenic therapies is one of the
important aims of our research laboratory. Because of the consid-
erable advantages of oral treatment above other treatments, we
attempted to find clinically available oral drugs with potent anti-
angiogenic activity. It has been demonstrated that the growth of
V2 carcinoma in rabbits can be inhibited by antiangiogenic agents
(Gross et al, 1981; Kamei et al, 1993). In this study, we found 55%
tumour growth inhibition by oral treatment of V2-carcinoma-
bearing rabbits with thalidomide. Our finding is in contrast to two
other recently published studies, in which thalidomide failed to
inhibit primary tumour growth in mice (Gutman et al, 1996;
Minchinton et al, 1996). We attributed this discrepancy to the well-
known differences in metabolism of thalidomide in rodents
compared with rabbits or humans (Schumacher et al, 1965, 1968).
Teratogenic malformations were detected after oral administration
of thalidomide to rabbits and humans, but not detected in mice
(Plies, 1962; Szabo and Steelman, 1967). In mice, thalidomide is
only antiangiogenic when given i.p. at a dose of 200 mg kg–1
(Kenyon et al, 1997). Unfortunately, in these other negative rodent
tumour studies, they used approximately 4 mg kg–1 day–1 i.p.
(Minchinton et al, 1996) or 12–40 mg kg–1 day–1 p.o. of thalido-
mide (Gutman et al, 1996). However, despite the use of such a low
dose (4 mg kg–1 day–1 i.p.) of thalidomide, there was still inhibition
of growth of lung metastases in Lewis lung carcinoma-bearing
mice (Minchinton et al, 1996).
When we combined thalidomide with sulindac in the corneal
neovascularization assay, we found a significantly enhanced
antiangiogenic effect of the combination compared with either
agent alone. As thalidomide and sulindac can be given as long-
term treatment, we tested the oral combination in the V2-carci-
noma model and found that the combination can inhibit tumour
vascularity by 56% and tumour growth by 75%. It is among the
most effective tumour inhibitions observed by an oral antiangio-
genesis therapy in our laboratory. In addition to the promising
preliminary results of the phase 1 clinical trials of thalidomide in
Kaposi sarcoma and glioblastoma patients (Fine et al, 1997; Little
et al, 1997), we provide here a potential application for combina-
tion of oral antiangiogenic therapy.
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